Vitrolife has received the Chinese State Food and Drug Administration (SFDA) approval for its aspiration needles and micropipettes used for infertility treatment (IVF).
The approval affirms that the product is certified, safe and efficient which is made available for IVF professionals.
Vitrolife develops advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs.
Vitrolife Representative Office chief Joe Jin said it is now able to provide not only the culture media products, but also the needles and micropipettes used in ovum pick up and microinjection procedures.
"This has opened up a new possibility to further leverage our growing sales in China," Jin said.